CompletedNCT03259282GAMESUpdated Apr 12, 2018

Gammaglobulins Level is Predictive Factor of Evolution in Sarcoidosis

An observational study in Sarcoidosis, sponsored by Rennes University Hospital. Completed at 1 site in France. Per ClinicalTrials.gov, last updated 2018-04-12.

Sponsored by Rennes University Hospital · Observational

Study type: Observational
Model: Case-only
Time perspective: Retrospective
Enrollment: 78
Sex: All

Study summary

Evaluation of the rate of achievement of serum protein electrophoresis (PPE) in diagnosis in a retrospective cohort of patients at Rennes University Hospital

Read the detailed description

In 50% of cases, sarcoidosis is associated with polyclonal hypergammaglobulinemia. The other forms have a normal gamma globulin level.

The level of gamma globulinemia has not yet been studied as an evolutionary predictive factor. Furthermore, there are disseminated granulomatoses sharing common characteristics with sarcoidosis, associated with Common Variable Immunodeficiency deficit (DICV) type Primary Immunodeficiency syndrome (DIP), thus occurring in hypogammaglobulinemic patients.

Conditions studied

Sarcoidosis

Browse trials for

Sarcoidosis 278

Who can participate

Ages eligible: Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible: All
Accepts healthy volunteers: No
Sampling method: Non-probability sample

Study population

Patients with sarcoidosis

Inclusion criteria

Patients newly diagnosed with sarcoidosis

Exclusion criteria

Exclusion Criteria:

Comorbidity responsible for a change in the level of gamma globulin
Other etiology of granulomatosis

Study design

Observational model: Case-only
Time perspective: Retrospective
Enrollment: 78 participants (actual)
Patient registry: No

Interventions

BiologicalAnalysis of gamma globulin
Electrophoresis of proteins

What researchers measure

Primary outcomes

Study of gamma globulin level present in the blood at the time of diagnosis of sarcoidosis on disease activity
Electrophoresis rates of serum proteins
Time frame: Day 1
Study of gamma globulin level present in the blood at the time of diagnosis of sarcoidosis on the course of the disease
Electrophoresis rates of serum proteins
Time frame: Day 1

Study locations

1 site

CHU de Rennes
Rennes, 35033, France

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

Registry details

Key details

Study ID: NCT03259282
Lead sponsor: Rennes University Hospital
Responsible party: Sponsor
First posted: Aug 23, 2017
Start date: Mar 7, 2017
Primary completion: Mar 22, 2017
Completion: Mar 22, 2017
Last update: Apr 12, 2018

Oversight

Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Sarcoidosis→

Other studies from this sponsor

Rennes University Hospital

Start the discussion